The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
103
Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks After 15Dec2009: ELND005 250 mg PO BID for 48 weeks
Treatment Emergent Adverse Events (TEAEs)
Safety and Tolerability was assessed by the incidence of Treatment Emergent Adverse Events (TEAEs)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Banner Alzheimer's Institute
Phoenix, Arizona, United States
Sun Health Research Institute
Sun City, Arizona, United States
University of Arizona, Health Sciences Center, Dept. of Neurology
Tucson, Arizona, United States
Margolin Brain Institute
Fresno, California, United States
Collaborative NeuroScience Network, Inc.
Garden Grove, California, United States
Yale University School of Medicine, Alzheimer's Disease Research Unit
New Haven, Connecticut, United States
Brain Matters Research
Delray Beach, Florida, United States
Sunrise Clinical Research, Inc
Hollywood, Florida, United States
Roskamp Institute
Sarasota, Florida, United States
Premiere Research Institute
West Palm Beach, Florida, United States
...and 28 more locations